As the country sees signs of a resurgence led by a subvariant of fast-spreading omicron, Japan's health ministry on Tuesday formally approved Novavax's COVID-19 vaccine, a fourth foreign-developed tool to tackle the diseases. The ministry's permission comes a day after an expert panel recommended that the first two injections and a booster be given with Novavax's protein vaccine, which was developed using similar technologies to battle diseases like the flu and hepatitis B.
Novavax, according to Health Minister Shigeyuki Goto, offers a variety of available options and may appeal to individuals who are afraid to employ COVID-19 vaccines like Pfizer's and Moderna's, which are built with modern technology. Jabs with the Novavax vaccination are planned to begin in late May.
The health ministry in Japan recorded 24,164 new cases on Monday. As infections dropped, Japan lifted all COVID-19 restrictions in March, but experts noticed symptoms of a return in a number of prefectures during a season of travel and parties for people celebrating graduation and the start of the academic and business year.
The government is trying to develop enterprises and resurrect the pandemic-ravaged economy. Japan is gradually loosening border controls in response to harsh criticism of its long-standing restrictions on non-resident foreign students, intellectuals, and businesspeople, but Prime Minister Fumio Kishida has stated that inbound tourism would not be resumed anytime soon. Booster shots have been slow in Japan, with less than half of the population receiving booster shots from Pfizer and Moderna, mostly mRNA vaccines.
Heart-related diseases can also be treated with corona vaccine
Booster dose will not be used for free, know the answer to every question related to it
